10 results about "Agrin" patented technology

The present invention relates to modified recombinant agrin proteins or fragments thereof and recombinant chimeric laminin-nidogen proteins or fragments thereof, nucleic acid sequences encoding these proteins, vectors containing these nucleic acid sequences, compositions comprising these proteins, and the use of these proteins in the prevention and / or treatment of congenital muscular dystrophies, in particular (laminin-α2) LAMA2-associated muscular dystrophy.

A mesoangioblast composition is disclosed, in which the mesoangioblasts (MABs) are engineered to express a truncated agrin protein.

The present invention discloses a negative regulation mechanism, experimental method and application of the Agrin-MuSK-DOK7 signaling pathway. After Agrin stimulates myotubes to activate MuSK, MuSK promotes phosphorylation of DOK7 Tyr106. With the help of CDH1, APC2 binds to DOK7 phosphorylated at Tyr106 and mediates ubiquitination of DOK7 Lys243 mainly in the form of K48 connection, promoting the degradation of DOK7 through the proteasome system, and ultimately leading to downregulation of DOK7 protein level, thereby achieving negative regulation of the Agrin-MuSK-DOK7 signaling pathway. In the present invention, APC2 CDH1 By promoting the ubiquitination and degradation of DOK7, negative regulation of the Agrin-MuSK-DOK7 signaling pathway is achieved, avoiding excessive activation of the Agrin-MuSK-DOK7 signaling pathway leading to abnormal NMJ development. The present invention provides a new theoretical basis for a deeper understanding of the molecular mechanism of neuromuscular junction development, and also provides new ideas for the development of treatment methods for related diseases.

The present invention relates to a modified recombinant agrin protein or a fragment thereof and a recombinant chimeric laminin-nidogen protein or a fragment thereof, to nucleic acid sequences encoding these proteins, to vectors comprising these nucleic acid sequences, to compositions comprising these proteins and to uses of these proteins in the prophylaxis and / or treatment of congenital muscular dystrophies, in particular (laminin-α2) LAMA2-related muscular dystrophy.

The invention relates to the proteins Agrin, Zyxin, Synaptotagmin-5, and combinations thereof, as well as the gene transcripts form the corresponding genes, as biomarkers of a hypoxic-ischemic encephalopathy (HIE).

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The invention provides an engineering scaffold for spinal cord injury repair and a construction method thereof.The engineering scaffold comprises a columnar scaffold body and a tubular mantle wrapping the outer side wall of the columnar scaffold body, and the columnar scaffold body is of a porous structure made of porous gelatin sponge; neural stem cells transfected by AdV-TrkC and Schwann cells transfected by AdV-NT-3 are distributed in the porous structure, and the neural stem cells and the Schwann cells are distributed in the porous structure. AAV-CMV-MuSK-GFP (DJ type) adeno-associated vector viruses and rAAV-hSyn-agrin-mCherry adeno-associated vector viruses are further distributed in the porous structure in a dispersed mode. The engineering scaffold can activate a target neuronal mitogen activated protein kinase adenosine cyclophosphate effect element binding protein signal channel and promote transmission of synaptic signals between neurons, so that repair of spinal cord injury is promoted, connection recovery of neurons and an injury part is effectively promoted, and the treatment effect of the spinal cord injury is further enhanced.

This invention provides a monoclonal antibody against the Agrin protein and its applications, belonging to the field of immunoassay technology. The monoclonal antibody is secreted by a hybridoma cell line with accession number CCTCC NO: C2025396 and specifically recognizes a key epitope in the Z8 region of the human Agrin protein. Based on this monoclonal antibody and / or the Agrin Z8 peptide, this invention constructs a kit for detecting anti-Agrin Z8 antibodies in the serum of patients with myasthenia gravis. The Agrin monoclonal antibody is used as a positive control or quantitative standard in this kit. Furthermore, this Agrin monoclonal antibody can be used to construct animal models of myasthenia gravis to study the pathogenesis of the disease. The Agrin monoclonal antibody provided by this invention has high specificity and high affinity, providing a key tool for the standardized diagnosis of myasthenia gravis and an effective means for studying its pathogenesis.

The present invention relates to a MuSK antibody-based molecule for use in the prevention or treatment of a disease or condition resulting from Agrin deficiency in a human subject.